Multiple-dose phase I trial to evaluate the tolerability and pharmacokinetics of NGX 426 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2009
At a glance
- Drugs Dasolampanel (Primary)
- Indications Migraine; Neuropathic pain; Pain
- Focus Adverse reactions
- Sponsors TorreyPines Therapeutics Inc
- 11 Feb 2009 Results were reported in a media release from TorreyPines Therapeutics.
- 11 Feb 2009 Status changed from recruiting to completed, as reported in media release from TorreyPines Therapeutics.
- 10 Oct 2008 New trial record.